The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

Science Translational Medicine

Volumn 8, Issue 330, 2016, Pages

  Kirkpatrick, Beth D ^a   Whitehead, Stephen S ^b   Pierce, Kristen K ^a   Tibery, Cecilia M ^c   Grier, Palmtama L ^c   Hynes, Noreen A ^d   Larsson, Catherine J ^a   Sabundayo, Beulah P ^c   Talaat, Kawsar R ^c   Janiak, Anna ^c   Carmolli, Marya P ^a   Luke, Catherine J ^d   Diehl, Sean A ^a   Durbin, Anna P ^c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; PROTHROMBIN; THROMBOPLASTIN; LIVE VACCINE;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; DRUG EFFICACY; DRUG RESEARCH; DRUG TOLERABILITY; EYE PAIN; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERAMYLASEMIA; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MACULOPAPULAR RASH; MALE; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEROCONVERSION; SEROTYPE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIREMIA; VIRUS STRAIN; BIOLOGICAL MODEL; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIROLOGY;

ADULT; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; VACCINATION; VACCINES, ATTENUATED; VIREMIA;

EID: 84962586730     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf1517     Document Type: Article

References (35)

1. S. Bhatt, P. W. Gething, O. J. Brady, J. P. Messina, A. W. Farlow, C. L. Moyes, J. M. Drake, J. S. Brownstein, A. G. Hoen, O. Sankoh, M. F. Myers, D. B. George, T. Jaenisch, G. R. W. Wint, C. P. Simmons, T. W. Scott, J. J. Farrar, S. I. Hay, The global distribution and burden of dengue. Nature 496, 504-507 (2013).
2. S. C. Kliks, S. Nimmanitya, A. Nisalak, D. S. Burke, Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38, 411-419 (1988).
3. D. S. Burke, A. Nisalak, D. E. Johnson, R. M. Scott, A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38, 172-180 (1988).
4. S. B. Halstead, Antibodies determine virulence in dengue. Ann. N.Y. Acad. Sci. 1171 (Suppl. 1), E48-E56 (2009).
5. S. B. Halstead, N. J. Marchette, J. S. Sung Chow, S. Lolekha, Dengue virus replication enhancement in peripheral blood leukocytes from immune human beings. Proc. Soc. Exp. Biol. Med. 151, 136-139 (1976).
6. S. B. Halstead, Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60, 421-467 (2003).
7. Live dengue Vaccines Technical Consultation Reporting Group, A. D. Bentsi-Enchill, J. Schmitz, R. Edelman, A. Durbin, J. T. Roehrig, P. G. Smith, J. Hombach, J. Farrar, Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. Vaccine 31, 2603-2609 (2013).
8. A. P. Durbin, B. D. Kirkpatrick, K. K. Pierce, D. Elwood, C. J. Larsson, J. C. Lindow, C. Tibery, B. P. Sabundayo, D. Shaffer, K. R. Talaat, N. A. Hynes, K. Wanionek, M. P. Carmolli, C. J. Luke, B. R. Murphy, K. Subbarao, S. S. Whitehead, A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial. J. Infect. Dis. 207, 957-965 (2013).
9. A. Sabchareon, D. Wallace, C. Sirivichayakul, K. Limkittikul, P. Chanthavanich, S. Suvannadabba, V. Jiwariyavej, W. Dulyachai, K. Pengsaa, T. A. Wartel, A. Moureau, M. Saville, A. Bouckenooghe, S. Viviani, N. G. Tornieporth, J. Lang, Protective efficacy of the recombinant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 380, 1559-1567 (2012).
10. M. R. Capeding, N.H. Tran, S. R. S. Hadinegoro, H. I. H. J. Muhammad Ismail, T. Chotpitayasunondh, M. N. Chua, C. Q. Luong, K. Rusmil, D. N. Wirawan, R. Nallusamy, P. Pitisuttithum, U. Thisyakorn, I.-K. Yoon, D. van der Vliet, E. Langevin, T. Laot, Y. Hutagalung, C. Frago, M. Boaz, T. A. Wartel, N. G. Tornieporth, M. Saville, A. Bouckenooghe; CYD14 Study Group, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384, 1358-1365 (2014).
11. L. Villar, G. H. Dayan, J. L. Arredondo-García, D. M. Rivera, R. Cunha, C. Deseda, H. Reynales, M. S. Costa, J. O. Morales-Ramírez, G. Carrasquilla, L. C. Rey, R. Dietze, K. Luz, E. Rivas, M. C. Miranda Montoya, M. Cortés Supelano, B. Zambrano, E. Langevin, M. Boaz, N. Tornieporth, M. Saville, F. Noriega; CYD15 Study Group, Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372, 113-123 (2015).
12. S. R. Hadinegoro, J. L. Arredondo-García, M. R. Capeding, C. Deseda, T. Chotpitayasunondh, R. Dietze, H. I. H. J. Muhammad Ismail, H. Reynales, K. Limkittikul, D. M. Rivera-Medina, H. N. Tran, A. Bouckenooghe, D. Chansinghakul, M. Cortés, K. Fanouillere, R. Forrat, C. Frago, S. Gailhardou, N. Jackson, F. Noriega, E. Plennevaux, T. A. Wartel, B. Zambrano, M. Saville; CYD-TDV Dengue Vaccine Working Group, Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195-1206 (2015).
13. S. A. Plotkin, Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055-1065 (2010).
14. A. Srikiatkhachorn, I.-K. Yoon, Immune correlates for dengue vaccine development. Expert Rev. Vaccines 10.1586/14760584.2016.1116949 (2015).
15. A. P. Durbin, S. S. Whitehead, J.McArthur, J. R. Perreault, J. E. Blaney Jr., B. Thumar, B. R.Murphy, R. A. Karron, rDEN4D30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191, 710-718 (2005).
16. A. P. Durbin, J. H. McArthur, J. A. Marron, J. E. Blaney, B. Thumar, K. Wanionek, B. R. Murphy, rDEN2/4D30(ME), a live attenuated chimeric dengue serotype 2 vaccine, is safe and highly immunogenic in healthy dengue-naïve adults. Hum. Vaccin. 2, 255-260 (2006).
17. A. P. Durbin, J. McArthur, J. A. Marron, J. E. Blaney Jr., B. Thumar, K. Wanionek, B. R. Murphy, S. S. Whitehead, The live attenuated dengue serotype 1 vaccine rDEN1D30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin. 2, 167-173 (2006).
18. A. P. Durbin, B. D. Kirkpatrick, K. K. Pierce, A. C. Schmidt, S. S. Whitehead, Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29, 7242-7250 (2011).
19. B. D. Kirkpatrick, A. P. Durbin, K. K. Pierce, M. P. Carmolli, C. M. Tibery, P. L. Grier, N. Hynes, S. A. Diehl, D. Elwood, A. P. Jarvis, B. P. Sabundayo, C. E. Lyon, C. J. Larsson, M. Jo, J. M. Lovchik, C. J. Luke, M. C.Walsh, E. A. Fraser, K. Subbarao, S. S. Whitehead, Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 212, 702-710 (2015).
20. D. J. Gubler, D. Reed, L. Rosen, J. C. Hitchcock Jr., Epidemiological, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am. J. Trop. Med. Hyg. 27, 581-589 (1978).
21. J. E. Blaney Jr., C. T. Hanson, K. A. Hanley, B. R. Murphy, S. S. Whitehead, Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 4, 39 (2004).
22. C. P. Larsen, S. S. Whitehead, A. P. Durbin, Dengue human infection models to advance dengue vaccine development. Vaccine 33, 7075-7082 (2015).
23. J. F. Siler, M. W. Hall, A. P. Hitchens, Dengue: Its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philippine J. Sci. 29, 1-304 (1926).
24. I.-K. Yoon, A. L. Rothman, D. Tannitisupawong, A. Srikiatkhachorn, R. G. Jarman, J. Aldstadt, A. Nisalak, M. P. Mammen Jr., S. Thammapalo, S. Green, D. H. Libraty, R. V. Gibbons, A. Getis, T. Endy, J. W. Jones, C. J. M. Koenraadt, A. C. Morrison, T. Fansiri, C. Pimgate, T. W. Scott, Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages. J. Infect. Dis. 206, 389-398 (2012).
25. V. Duong, L. Lambrechts, R. E. Paul, S. Ly, R. S. Lay, K. C. Long, R. Huy, A. Tarantola, T. W. Scott, A. Sakuntabhai, P. Buchy, Asymptomatic humans transmit dengue virus to mosquitoes. Proc. Natl. Acad. Sci. U.S.A. 112, 14688-14693 (2015).
26. R. W. Sauerwein, M. Roestenberg, V. S. Moorthy, Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11, 57-64 (2011).
27. W. Sun, K. H. Eckels, J. R. Putnak, A. G. Lyons, S. J. Thomas, D.W. Vaughn, R. V. Gibbons, S. Fernandez, V. J. Gunther, M. P. Mammen Jr., J. D. Statler, B. L. Innis, Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J. Infect. Dis. 207, 700-708 (2013).
28. A. B. Sabin, Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1, 30-50 (1952).
29. M. Montoya, L. Gresh, J. C. Mercado, K. L. Williams, M. J. Vargas, G. Gutierrez, G. Kuan, A. Gordon, A. Balmaseda, E. Harris, Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLOS Negl. Trop. Dis. 7, e2357 (2013).
30. D. Morrison, T. J. Legg, C. W. Billings, R. Forrat, S. Yoksan, J. Lang, A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201, 370-377 (2010).
31. J. Poo, F. Galan, R. Forrat, B. Zambrano, J. Lang, G. H. Dayan, Live-Attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico city: Randomized controlled phase 1 trial of safety and immunogenicity. Pediatr. Infect. Dis. J. 30, e9-e17 (2011).
32. D.Weiskopf, M. A. Angelo, E. L. de Azeredo, J. Sidney, J. A. Greenbaum, A. N. Fernando, A. Broadwater, R. V. Kolla, A. D. De Silva, A. M. de Silva, K. A. Mattia, B. J. Doranz, H. M. Grey, S. Shresta, B. Peters, A. Sette, Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A. 110, E2046-E2053 (2013).
33. D. Weiskopf, M. A. Angelo, D. J. Bangs, J. Sidney, S. Paul, B. Peters, A. D. de Silva, J. C. Lindow, S. A. Diehl, S. Whitehead, A. Durbin, B. Kirkpatrick, A. Sette, The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J. Virol. 89, 120-128 (2015).
34. G. H. Dayan, M. Thakur, M. Boaz, C. Johnson, Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 31, 5047-5054 (2013).
35. A. P. Durbin, R. A. Karron, W. Sun, D. W. Vaughn, M. J. Reynolds, J. R. Perreault, B. Thumar, R. Men, C.-J. Lai, W. R. Elkins, R. M. Chanock, B. R. Murphy, S. S. Whitehead, Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3?-untranslated region. Am. J. Trop. Med. Hyg. 65, 405-413 (2001).